ZOLINZA Drug Patent Profile
✉ Email this page to a colleague
When do Zolinza patents expire, and what generic alternatives are available?
Zolinza is a drug marketed by Msd Sub Merck and is included in one NDA. There are five patents protecting this drug.
This drug has one hundred and thirty-one patent family members in thirty-five countries.
The generic ingredient in ZOLINZA is vorinostat. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vorinostat profile page.
DrugPatentWatch® Generic Entry Outlook for Zolinza
Zolinza was eligible for patent challenges on October 6, 2010.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 11, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZOLINZA?
- What are the global sales for ZOLINZA?
- What is Average Wholesale Price for ZOLINZA?
Summary for ZOLINZA
International Patents: | 131 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 136 |
Clinical Trials: | 161 |
Patent Applications: | 4,498 |
Drug Prices: | Drug price information for ZOLINZA |
What excipients (inactive ingredients) are in ZOLINZA? | ZOLINZA excipients list |
DailyMed Link: | ZOLINZA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZOLINZA
Generic Entry Date for ZOLINZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ZOLINZA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
OHSU Knight Cancer Institute | Phase 1 |
Prospect Creek Foundation | Phase 1 |
Oregon Health and Science University | Phase 1 |
Pharmacology for ZOLINZA
Drug Class | Histone Deacetylase Inhibitor |
Mechanism of Action | Histone Deacetylase Inhibitors |
US Patents and Regulatory Information for ZOLINZA
ZOLINZA is protected by five US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZOLINZA is ⤷ Subscribe.
This potential generic entry date is based on patent ⤷ Subscribe.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZOLINZA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Subscribe | ⤷ Subscribe |
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Subscribe | ⤷ Subscribe |
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Subscribe | ⤷ Subscribe |
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZOLINZA
See the table below for patents covering ZOLINZA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Norway | 20044112 | ⤷ Subscribe | |
Poland | 379887 | Sposób leczenia raka inhibitorami HDAC (METHOD OF TREATING CANCER WITH HDAC INHIBITORS) | ⤷ Subscribe |
Israel | 197582 | תכשירים רוקחיים המכילים צורה קריסטלינית של חומצה הידרקוסמית של סברואילאניליד (saha) ושיטות להכנת saha (Pharmaceutical compositions comprising a crystalline form of suberoylanilide hydroxamic acid (saha) and methods for saha preparation) | ⤷ Subscribe |
China | 101080223 | Formulations of suberoylanilide hydroxamic acid and methods for producing same | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
ZOLINZA Market Analysis and Financial Projection Experimental
More… ↓